What is Celldex Therapeutics's stock issuance proceeds?

Celldex Therapeutics (CLDX) reported stock issuance proceeds of $327K in Q1 2026.

How has Celldex Therapeutics's stock issuance proceeds changed year-over-year?

Celldex Therapeutics's stock issuance proceeds increased by 61.9% year-over-year, from $202K to $327K.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Celldex Therapeutics CLDX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

IncyteINCY

$97.93M+2,923%

Arcutis Biotherapeutics, Inc.ARQT

$1.07M—

Nurix Therapeutics, Inc.NRIX

$18M—

Viridian Therapeutics, Inc.VRDN

$0-100%

CelcuityCELC

$206K—

Other financials

Income statement

See full

Revenue$15.0K-97.8%

Operating income-$84.4M-34.6%

Net income-$78.7M-46.3%

EPS (diluted)-$1.18-45.7%

Balance sheet

See full

Cash & equivalents$35.7M+109%

Total debt$1.9M-44.3%

Total equity$456.2M-35.1%

Total assets$511.3M-30.9%

Cash flow

See full

Operating cash flow-$65.6M-20.6%

CapEx$1.6M+518%

Free cash flow-$67.2M-23.0%

Valuation

See full

Market cap$2.59B+75.2%

Enterprise value$2.55B+74.4%

P/S2,989.2×+2,794×

Profitability

See full

Operating margin-35,688.5%-39,114pp

Net margin-32,753.6%-35,519pp

FCF margin-26,125.8%-28,907pp

Returns & leverage

See full

Return on equity-48.9%-498pp

Debt / equity0×0.0×

Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Celldex Therapeutics's stock issuance proceeds?: Celldex Therapeutics (CLDX) reported stock issuance proceeds of $327K in Q1 2026.
How has Celldex Therapeutics's stock issuance proceeds changed year-over-year?: Celldex Therapeutics's stock issuance proceeds increased by 61.9% year-over-year, from $202K to $327K.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.